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Summary We investigated the prognostic value of the serum half-life of human chorionic gonadotrophin (HCG) and alpha-fetoprotein (AFP)
during induction chemotherapy and the relative prognostic importance of initial marker concentrations and marker half-life. Marker half-lives
were calculated using two abnormal values observed between day 8 and day 22 of the first chemotherapy cycle. Moreover, analyses were
carried out using day 43 as the second measurement point. Treatment failure at any time was chosen as the end point. The relative
prognostic influence of marker half-lives and initial marker concentrations was tested in univariate and multivariate analyses. Half-lives were
considered to be prolonged if > 3 days for HCG and > 6 days for AFP. In addition, we separated patients into those with half-lives > 6 days for
HCG and those with half-lives > 10 days for AFP to examine whether these long half-lives were associated with a poor prognosis. A group of
669 patients treated with cisplatin combination chemotherapy was studied. Forty-two per cent of the patients had normal HCG and 37% had
normal AFP at the start of chemotherapy. At day 22, HCG was still elevated in 138 patients and AFP in 211. At day 43, the numbers of these
patients were 35 and 80 respectively. Based on the measurements obtained on day 8 and day 22, a half-life of HCG > 3 days or > 6 days
and/or a half-life AFP > 6 days or > 10 days did not accurately predict treatment failure (P=0.413 and P=0.851, respectively; values obtained
using tests for trend). However, initial marker concentrations of HCG and/or AFP . 1000 IU 1-1 were highly significant prognosticators for
treatment failure (P=0.001 and P< 0.001 respectively), independent of half-life values. Half-lives calculated with the values obtained on day
43 did not contribute to the accuracy of the prediction of treatment failure. We conclude that half-lives of HCG and AFP during induction
chemotherapy are inaccurate parameters for the prediction of treatment failure. In contrast, initial serum concentrations of HCG and AFP are
highly significant in the prediction of unfavourable treatment outcome.
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Cisplatin combination chemotherapy yields 60-70% long-term
disease-free survival in patients with disseminated testicular non-
seminoma (Levi et al, 1988; Peckham et al, 1988; Roth et al, 1988;
Stoter et al, 1989). Patients who fail treatment are usually charac-
terized by a high tumour load and/or high serum concentration of
tumour markers. Multivariate analyses of prognostic factors have
led to the development of models that can be used to classify
patients as having good or poor prognosis (Bosl et al, 1983;
Medical Research Council Working Party on Testicular Tumours,
1985; Birch et al, 1986; Stoter et al, 1987; Droz et al, 1988;
Hitchins et al, 1989; Stoter and Sylvester, 1990; Aass et al, 1991;
Mead et al, 1992). The shortcomings ofthese models are that they
are not uniform and that there is a varying proportion of patients
who are deemed as having a poor prognosis but actually have a
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good prognosis, and they are thus unnecessarily exposed to the
risks of intensified chemotherapy regimens (Bajorin et al, 1988).
Consequently, it would be useful to have a method for early
prediction of failure to conventional chemotherapy in the indi-
vidual patient using the natural half-life of the tumour markers
human chorionic gonadotrophin (HCG) and alpha-fetoprotein
(AFP) during induction chemotherapy (Kohn, 1979). However,
there is controversy regarding the usefulness of these parameters
(Toner et al, 1990; Stevens and Horwich, 1995). Therefore, we
investigated the prognostic value of marker half-lives during the
first cycle as well as the first two cycles of induction chemo-
therapy in patients with metastatic non-seminomatous testicular
cancer. Several prognostic factor analyses have shown that marker
concentrations at the start of chemotherapy are very important
determinants for treatment outcome (Medical Research Council
Working Party on Testicular Tumours, 1985; Birch et al, 1986;
Stoter et al, 1987; Stoter and Sylvester, 1990; Aass et al, 1991;
Mead et al, 1992). The most recent EORTC prognostic factors
analysis has yielded cut-off values for HCG and AFP of 1000 IU
l-'. Consequently, we investigated the relative importance of
marker half-lives and initial marker concentrations.
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PATIENTS AND METHODS
Patients
Six hundred and sixty-nine patients with disseminated non-
seminomatous testicular cancer were treated with cisplatin combi-
nation chemotherapy in the framework oftwo randomized studies
of the European Organization for Research and Treatment of
Cancer (EORTC) (Stoter et al, 1991; de Wit et al, 1995). In the
first study, 250 patients with lymph node metastases 2 5 cm and/or
lung metastases > 2 cm and/or HCG > 10 000 IU 1-1 and/or AFP 2
1000 IU l-l were treated with cisplatin, etoposide and bleomycin
(BEP) or an alternating regimen of BEP and cisplatin, vinblastine
and bleomycin (PVB). In the other study, 419 patients who had
smaller metastases and lower marker levels than specified above
were treated with BEP or etoposide and cisplatin (EP). In both
protocols, induction chemotherapy consisted of four treatment
cycles for a total duration of 12 weeks. After four cycles of
chemotherapy, patients with normal markers and no residual
tumour mass did not receive further therapy. Patients with normal
markers but residual tumour mass were subjected to debulking
surgery. In case of viable cancer in the surgical specimens, two
additional cycles ofchemotherapy were given.
At the time ofthis analysis, the follow-up time ranged from 4 to
10 years. Treatment failure was defined as elevated tumour
markers afterfourinduction chemotherapy cycles,viable cancerin
the resected specimens, relapse from complete response or death
owing to malignant disease at any time. There was no difference
between the treatment regimens in these randomized studies.
The model
As we observed a surge of HCG and AFP in 28% and 34% of our
patients respectively, we decided to calculate half-lives by using the
maximum value observed around day 8 as the first measurement
point (To) and day 22 as the second (T,). A separate analysis was
performedbasedon the measurements ofday 8(To) anddays43 (T2).
The serum half-life (T,12 of HCG and AFP) was calculated









conc. T, log,o conc. T
in which T is the time between To (day 8) and T, (day 22) or
between To and T2 (day 43), and conc. is the serum marker concen-
tration. According to expected mean half-lives during chemo-
therapy (Vogelzang et al, 1982), the patients presented here were
categorized according to a half-life below or above 3 days for
HCG and below or above 6 days for AFP. An additional analysis
was performed in patients with very long half-lives of> 6 days for
HCG and > 10 days for AFP.
RESULTS
HCG and AFP values at the start of treatment and on day 22 were
available in 526 and 537 patients respectively. Forty-two per cent
of patients had initial normal HCG and 37% normal AFP. As
marker concentrations at the start of treatment are very important
determinants for treatment outcome, patients were stratified for
initial values above or below 1000 IU 1-'. Table 1 shows the
numbers of the patients in the different categories and the corre-
sponding treatment failure rates.
Table 1 Relationship between HCG and AFP at day 22 and treatment failure
according to initial marker concentrations
Initial values
Normal value < 1000 > 1000 Total
Treatment failure
HCG at day 22
Normal 18/180 (10) 19/176 (11) 0/0 ( 0) 37/356 (10)
Abnormal 0/1 ( 0) 21/106 (20) 18/63 (29) 39/170 (23)
Total 18/181 (10) 40/282 (14) 18/63 (29) 76/526 (14)
AFP at day 22
Normal 16/164 (10) 11/115 (10) 0/0 ( 0) 27/279 (10)
Abnormal 0/3 ( 0) 30/200 (15) 20/55 (36) 50/258 (19)
Total 16/167(10) 41/315 (13) 20/55 (36) 77/537 (14)
Table 2 Relationship between HCG half-life and treatment failure according
to initial concentration, using day 22 as measurement point (T,)
HCG at entry (IU I-')
< 1000 >1000 Totala
Patients Failure Patients Failure Patients Failure
463 58 (13) 63 18(29) 526 76 (14)
T,/2
0-3 days 27 5 (19) 35 7 (20) 62 12 (19)
3-6days 41 8(20) 13 7(54) 54 15(28)
>6days 18 5 (28) 2 - 20 5 (25)
Totalb 87 18 (21) 51 15 (29) 138 33 (24)
aPatients for whom initial and day 22 values were available. bPatients for
whom a value around day 8 (To) and day 22 were available.
Table 3 Relationship between AFP half-life and treatment failure according
to initial concentration, using day 22 as measurement point (T,).
AFP at entry (IU 1-1)
< 1000 > 1000 Totala
Patients Failure Patients Failure Patients Failure
482 57 (12) 55 20 (36) 537 77 (14)
0-6days 66 9(14) 21 8(38) 87 17(20)
6-10 days 71 13 (18) 22 10 (46) 93 23 (25)
> 10 days 25 5 (20) 3 - 28 5 (18)
Totalb 165 27 (16) 46 18 (39) 211 45 (21)
aPatients for whom initial and day 22 values were available. bPatients for
whom a value around day 8 (To) and day 22 were available.
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Table 4 Relationship between HCG half-life and treatment failure according
to initial concentration, using day 43 as the second measurement point (T2)
HCG at entry (IU 1-1)
< 1000 .1000 Total
Patients Failure Patients Failure Patients Failure
12 6 (50) 23 8 (35) 35 14 (40)
0-3 days - - - - - -
3-6days - - 14 4 (29) 14 4 (29)
> 6 days 12 6 (50) 9 4 (44) 21 10 (48)
Total 12 6 (50) 23 8 (35) 35 14 (40)
Table 5 Relationship between AFP half-life and treatment failure according
to initial concentration, using day 43 as the second measurement point (T2)
AFP at entry (IU 1-1)
< 1000 . 1000 Total
Patients Failure Patients Failure Patients Failure
38 10 (25) 42 15 (36) 80 25 (30)
-6 days 11 2 (18) 24 10 (42) 35 12 (34)
6-10 days 14 2 (14) 16 5 (31) 30 7 (23)
> 10 days 13 6 (46) 2 - 15 6 (40)
Total 38 10 (25) 42 15 (36) 80 25 (30)
Half-lives can only be calculated if the markers have not
normalized before day 22, therefore the analyses presented below
concern only the patients who still have elevated values at day 22,
and for whom a value around day 8 as the first measurement point
(To) was available.
Consequently, half-lives using day 22 (T,) could be calculated in
138 out of 526 (26%) patients with HCG and in 211 out of 537
(39%) patients with AFP. Using day 43 (T2) as the second
measurement point for HCG and AFP, 35 out of 526 (7%) and 80
out of537 (15%) patients could be analysed.
Tables 2 and 3 show the treatment failure rates in patients with
HCG and AFP, respectively, using day 22 as measurement point.
Patients with a normal half-life forHCG (Table 2) have a failure
rate of 19%. Patients with a half-life of 3-6 days or > 6 days have
failure rates of 28% and 25% respectively (P=0.558 chi-square
overall; P=0.413 chi-square trend). The failure rates in patients
with initial HCG below or above 1000 IU 1-1 are 13% vs 29%
(P=0.001 chi-square corrected).
When we compare patients with a normal half-life for AFP
(Table 3) with patients with a prolonged half-life of6-10 days or>
10 days, the failure rates are 20%, 25% or 18% respectively
(P=0.611 chi-square overall; P=0.851 chi-square trend). The
failure rates in patients with initial AFPbelow orabove 1000 IU I-l
are 12% vs 36% (P<0.001 chi-square corrected).
A multivariate analysis based on the Cox's proportional hazards
regression model was carried out to determine the relative impor-
tance of marker half-lives and initial marker levels. For this
purpose multiple analyses were performed, based on different
groupings according to the values of half-lives and initial marker
concentrations. All analyses paralleled very closely the findings in
the univariate analysis in that initial marker values were predictive
for treatment failure, but half-lives were not.
Finally, Tables 4 and 5 show identical analyses as presented in
Tables 2 and 3, but using day 43 (T2) as the second measurement
point for half-life. It can be seen that the small numbers ofpatients
in the different categories do not allow statistically meaningful
calculations.
DISCUSSION
This analysis ofthe prognostic value of marker half-lives of HCG
and AFP to predict treatment failure was performed in a patient
population with a follow-up of 4-10 years, a time which allows
adequate observation of most failures.
Although at the start of chemotherapy 58% of the patients had
elevated HCG and 63% had elevated AFP, 51% of the patients in
the elevated HCG group and 31% of the patients in the elevated
AFP group had normal markers on day 22, i.e. at the start of the
second chemotherapy cycle. This means that half-lives could not
be calculated in these subgroups. It can be seen in Tables 2 and 3
that the prognostic value ofthe marker half-lives ofHCG and AFP
is significantly less predictive than the marker concentration at the
start of treatment. Even when separating out patients with
extremely prolonged half-lives of> 6 days for HCG and > 10 days
for AFP, treatment failure could not be accurately predicted. In
order to assess the relative importance of the initial marker levels
and marker half-lives, multivariate analyses were performed
which showed that initial marker levels were independent predic-
tors and more important than marker half-lives.
Investigators from Memorial Sloan Kettering Hospital (MSKCC)
have developed a prognostic model based on the half-life of HCG
and AFP during induction chemotherapy which would appear to
predict treatment failure with a high degree ofaccuracy (Toner et al,
1990; Motzer et al, 1993). Recently, investigators from the Royal
Marsden Hospital (RMH) reported thatthey were not able to predict
treatment failure on the basis of marker half-lives (Stevens and
Horwich, 1995). Intheiranalysis of 183 patients,thepredictive value
of treatment failure was around 20% in case of prolonged marker
half-life. The most important methodological difference between the
MSKCC analysis on the one hand,and the RMH and ouranalysis on
the otherhand, is that in the MSKCC analysis,patients with normal-
ized markers at the second measurement point were included in the
normal half-life group. As early normalization ofmarkers is usually
associated with low initial marker levels, which in itself is a good
prognostic variable,this may have influenced theirmodel. As can be
seen inTable 1,the treatmentfailure rate in ourpatients withnormal-
ized values atday 22 is only 11% for HCG and 10% forAFP.
Some investigators have made the point that marker half-lives
should be analysed over a longerinterval, i.e. with the values at the
start ofthe third treatment cycle (day 43). Although, in our hands,
only 25-40% of all treated patients still had elevated markers on
day 22 and only 7-15% still had elevated markers at day 43, we
performed such an analysis. However, as a result of the small
numbers ofpatients in the different categories, it was not possible
to draw meaningful statistical conclusions.
We conclude firstly that marker half-lives of HCG and AFP in
the first cycle orthe first two cycles ofinduction chemotherapy are
unreliable parameters for the prediction of treatment failure, and
secondly that initial marker concentrations are independent prog-
nostic factors and are highly significant parameters for the predic-
tion oftreatment failure.
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